CSF1R and central nervous system cancer: Similarly, Pradel et al. showed that after the administration of Emactuzumab (RG7155), another therapeutic anti-CSF-1R antibody, glioma cell-derived IL-4 was able to rescue GAM viability and thus counteracted CSF-1R treatment [150].